Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.52 |
| ▸ | PPIB | P23284 | 1/20 | 0.52 |
| ▸ | PPIG | Q13427 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17093004 | 0.89 | RIPK1 (0.51) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL16964986 | 0.84 | RIPK1 (0.48) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL22165570 | 0.83 | RIPK1 (0.47) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL23064471 | 0.82 | PPID (0.48) | PPIDPPIBPPIGBACE1SCD5 | |
| SCHEMBL28537451 | 0.82 | PPID (0.48) | PPIDPPIBPPIGBACE1SCD5 | |
| SCHEMBL6310168 | 0.81 | HSP90AA1 (0.61) | RIPK1HSP90AA1HSP90AB1 | |
| SCHEMBL28946650 | 0.81 | RIPK1 (0.46) | PPIDPPIBPPIGRIPK1HSP90AA1 | |
| SCHEMBL2325712 | 0.80 | NR1H2 (0.57) | PPIDPPIBPPIGSCD5RIPK1 | |
| SCHEMBL3312132 | 0.80 | NR1H2 (0.57) | PPIDPPIBPPIGSCD5RIPK1 | |
| SCHEMBL3313724 | 0.80 | NR1H2 (0.57) | PPIDPPIBPPIGSCD5RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2024-05-23 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-04-20 | — | — | US | disclosed |
| CN-115490708-A | Sulfonamide macrocyclic derivatives, and preparation method and application thereof | 苏州亚盛药业有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021133817-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2021-07-01 | — | — | WO | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020140005-A2 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-2356105-B1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | MSD OSS BV (NL) | 2013-04-10 | — | — | EP | disclosed |
| US-8188123-B2 | (Pyrrolidin-2-yl)phenyl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2012-05-29 | — | — | US | disclosed |
| EP-2356105-A1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | N.V. Organon (NL) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010052198-A1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | N.V. ORGANON (NL) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | N.V. ORGANON | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BCL3, BCL2L1 | PPID 208/4885PPIB 46/4885PPIG 37/4885 |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BAK1, BCL2A1 | PPID 129/4885PPIB 70/4885PPIG 154/4885 |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | CNR1, CNR2, TRPV1 | PPID 679/4885PPIB 573/4885PPIG 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.